Vasoconstrictor effect of the Ca2+ agonist Bay K 8644 on human cerebral arteries.
The effects of Bay K 8644 on the reactivity and 45Ca2+ uptake in segments from human cerebral arteries were studied. Bay K 8644 induced concentration-dependent contractions up to 10(-6) M; 10(-5) M produced a reduction of the maximal response. The Ca2+ agonist elicited these contractions by itself, and no previous depolarization was needed. The response to Bay K 8644 was antagonized competitively by nifedipine (5 x 10(-8) and 10(-7) M, pA2 value of 8.17) and non-competitively by verapamil (10(-6), 5 x 10(-6) and 10(-5) M). The contraction induced by 10(-7) M Bay K 8644 was inhibited by a Ca2+-free medium containing 1 mM EGTA. The subsequent cumulative Ca2+ addition, caused concentration-dependent contractions up to 2.5 mM Ca2+, which were reduced by nifedipine (10(-8) and 10(-7) M) or verapamil (5 x 10(-6) and 10(-5) M). When the EGTA concentration in the Ca2+-free solution was reduced to 0.1 mM, contractions induced by Ca2+ up to 5 mM, including 0 Ca2+, were increased with respect to those obtained in the presence of 1 mM EGTA. Basal 45Ca2+ uptake was not modified with Bay K 8644 (10(-6) M) or nifedipine (10(-6) M). K+ (25 and 50 mM) produced an increase on 45Ca2+ uptake, which was potentiated by Bay K 8644 (10(-6) M) and antagonized by nifedipine (10(-6) M); this latter agent reduced the potentiation elicited by the Ca2+ agonist.(ABSTRACT TRUNCATED AT 250 WORDS)
Salaices
M
M
Departamento de Farmacología y Terapéutica, Facultad de Medicina, Universidad Autónoma, Madrid, Spain.
Alonso
M J
MJ
Rico
I
I
Fernández-Alfonso
M S
MS
Marín
J
J
D001498:3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester / Q000494:pharmacology*; D002118:Calcium / Q000493:pharmacokinetics / Q000502:physiology*; D002121:Calcium Channel Blockers / Q000494:pharmacology*; D002536:Cerebral Arteries / Q000187:drug effects / Q000502:physiology*; D006801:Humans; D066298:In Vitro Techniques; D009131:Muscle, Smooth, Vascular / Q000187:drug effects / Q000378:metabolism / Q000502:physiology*; D009543:Nifedipine / Q000494:pharmacology; D014662:Vasoconstrictor Agents / Q000494:pharmacology*; D014700:Verapamil / Q000494:pharmacology
D002121:Calcium Channel Blockers; D014662:Vasoconstrictor Agents; D001498:3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester; D014700:Verapamil; D009543:Nifedipine; D002118:Calcium